To the editor:

**BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells**

Montes-Moreno et al recently reported the usefulness of SPIB as a novel immunohistochemical marker for supporting the diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The article highlights the well-recognized difficulty in approaching the diagnosis of BPDCN, in which transformed plasmacytoid dendritic cells (PDCs) frequently show loss and/or de novo expression of antigens that may lead to misdiagnosis. In the study of Montes-Moreno, all 44 cases of BPDCN were positive for SPIB, whereas the classical mimickers, including acute myeloid leukemia (AML) and precursor acute lymphoblastic leukemia (ALL), were regularly negative. Nevertheless, SPIB showed reactivity with normal B-cells and were labeled neoplastic cells of a large proportion (58%) of diffuse large B-cell lymphomas and of a minority (18%) of peripheral T-cell lymphomas.

Here, we would like to integrate data from the study of Montes-Moreno by proposing an anti-BDCA-2 (CD303) antibody as an additional tool in the BPDCN diagnostic panel. BDCA-2 is a type II C-type lectin receptor selectively expressed on PDCs, where it is involved in antigen capture and in regulation of the production of interferon type I. Dzionek et al originally described the specific reactivity with normal PDCs of the anti-BDCA-2 mouse clone AC144 applied on frozen tissue sections; subsequently, Jaye et al developed a rabbit polyclonal anti-BDCA-2 antibody in their laboratory that stained normal PDCs and BPDCN tumor cells on frozen and formalin-fixed paraffin-embedded tissue sections. Using a new anti-BDCA-2 mouse monoclonal antibody reactive on formalin-fixed paraffin-embedded tissue sections (clone 124B3.13; Dendritics, Lyon, France), we stained a large series of normal and reactive lymphoid tissues and found that this reagent is an excellent marker for human PDCs, being selectively and strongly expressed on these cells (Figure 1). Furthermore, the antibody stained neoplastic cells in 19 of 21 cases of BPDCN, whereas it was regularly negative in all samples from AML (n = 55, all FAB subtypes), ALL (n = 15, 10 B-cell and 5 T-cell type), diffuse large B-cell lymphomas (n = 35), and peripheral T-cell lymphoma (n = 25). These results support data from previous studies that used the same anti-BDCA-2 clone on a limited number of cases, thus indicating that this reagent has a very high specificity (100%), sensitivity (90.5%), and positive predictive value (100%) for BPDCN. Remarkably, the high level of performance of the clone 124B3.13 is unique among the large set of PDC markers commonly used for BPDCN diagnosis, such as CD123, TCL1, BCL11a, CD2AP, as well as SPIB. Moreover, our findings complement previously published data obtained by flow cytometry using the AC144 clone, that demonstrated that positivity for BDCA-2 has the highest diagnostic score within a panel of markers used for BPDCN identification and confirmed that BPDCN does not cross the boundary with other hematopoietic neoplasms.

Montes-Moreno et al concluded that SPIB expression supports the diagnosis of BPDCN in the appropriate clinicopathological setting, but needs to be evaluated in association with other immunohistochemical markers. Here, we propose that anti-BDCA-2 clone 124B3.13 should

![Figure 1](https://via.placeholder.com/150)
To the editor:

Molecular characterization of a transformation from primary myelofibrosis into polycythemia vera: a case report

Transformation of polycythemia vera (PV) into post-PV myelofibrosis (MF) occurs at a rate of 5.1 per 1000 person-years.1 The reverse of this transformation, from MF to PV, has been described2-5 but is rare, and these cases predate testing for the JAK2V617F mutation. Reverse transformation has not been described in 1000 cases of patients with primary myelofibrosis (PMF) seen at the Mayo Clinic.6 We wish to report a case of a patient who presented with PMF that subsequently evolved to PV. This report represents, to the best of our knowledge, the first published case report of a patient with “reversed” transformation that has undergone JAK2V617F confirmation.

A 51-year-old woman presented with weakness, fatigue, and progressive dyspnea. Examination revealed tachycardia, tachypnea, and massive splenomegaly. Initial laboratory studies showed normocytic anemia with a hemoglobin concentration of 8.8 g/dL, as well as profound leukopenia with repeated absolute neutrophil counts of less than 1000 K/uL. The platelet count was normal, and no circulating blasts were detected. Renal and hepatic function were within normal limits. Serum erythropoietin level was elevated at 80.5 mU/mL. A peripheral blood smear showed many teardrop red cells and rare nucleated erythrocytes. Ferritin level was with normal range (65 ng/mL). Bone marrow aspiration was cellular, and a bone marrow biopsy result revealed a hypocellular marrow with grade 3 to 4 fibrosis demonstrated by reticulum staining (Figures 1 and 2). There were no findings to suggest secondary fibrosis, and the patient was diagnosed with PMF, for which she received red blood cell transfusions.

At 1 year later, the patient remained transfusion dependent, and results on repeated bone marrow biopsy showed progressive fibrosis. During the course of the next year, cell counts for all 3 lineages were noted to spontaneously increase; therefore, transfusions were discontinued. The slow increase in cell counts continued without treatment, and after 4 years, both hemoglobin and platelet counts exceeded the normal range.

In 2007, testing for the JAK2V617F mutation revealed the presence of mutant alleles (not quantified). Total body red cell

References

BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells

Leonardo Boiocchi, Silvia Lonardi, William Vermi, Simona Fisogni and Fabio Facchetti